Reneo Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

OKUR$3.19+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and par value data)

	March 31,2024	December 31,2023
(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$20,375	$27,632
Short-term investments	62,460	75,331
Prepaid expenses and other current assets	1,092	3,659
Total current assets	83,927	106,622
Property and equipment, net	102	134
Right-of-use assets	546	599
Other non-current assets	64	81
Total assets	$84,639	$107,436
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$676	$8,717
Accrued expenses	1,807	9,129
Operating lease liabilities, current portion	331	331
Total current liabilities	2,814	18,177
Operating lease liabilities, less current portion	576	642
Performance award	7	7
Total liabilities	3,397	18,826
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 33,420,808 shares issued and outstanding at March 31, 2024 and December 31, 2023	3	3
Additional paid-in capital	308,151	307,073
Accumulated deficit	(226,900)	(218,474)
Accumulated other comprehensive (loss) income	(12)	8
Total stockholders’ equity	81,242	88,610
Total liabilities and stockholders’ equity	$84,639	$107,436

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.